-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Group Guolong Pharmaceutical has been awarded the title of “Provincial Demonstration Enterprise for Technological Innovation.”
Category:
Time：2022-01-20
Recently, the Hebei Provincial Department of Industry and Information Technology released the list of Hebei Province’s Demonstration Enterprises for Technological Innovation for 2021. Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guolong Pharmaceutical Co., Ltd. was recognized as a 2021 Hebei Province Demonstration Enterprise for Technological Innovation.
Recently, the Hebei Provincial Department of Industry and Information Technology released the list of Hebei Province’s Demonstration Enterprises for Technological Innovation for 2021. Shijiazhuang Siyao Group Hebei Guolong Pharmaceutical Co., Ltd. was recognized as a 2021 Hebei Province Demonstration Enterprise for Technological Innovation.
As a wholly-owned subsidiary of Shijiazhuang Sihua Pharmaceutical Group, Guolong Pharmaceutical has, in recent years, leveraged the group’s robust comprehensive strength and advanced management practices to vigorously implement a “bulk pharmaceutical ingredients + finished dosage forms” strategy. Using industry-academia-research-application collaboration as a key link, the company has focused on developing refined, diversified, and specialized products, and has been diligently building an enterprise-driven innovation system centered on technological platform development and new product R&D. It has continuously carried out technological upgrades, steadily promoted improvements in management, technology, products, environmental protection, and safety. As a result, a number of distinctive new products and breakthrough achievements in fields such as anti-infectives, blood volume expanders, respiratory medications, psychotropic drugs, and innovative pharmaceuticals have accelerated their implementation and industrialization. The company has established and cultivated a new model of sequential industrial development—“developing a batch, commercializing a batch, and reserving a batch”—leading to a significant increase in its product market share. This has provided the company with ample momentum for transformation, upgrading, and differentiated competition. Guolong Pharmaceutical has successively been recognized as a high-tech enterprise, an A-level R&D institution among industrial enterprises in Hebei Province, and a “Specialized, Fine, and New” small and medium-sized enterprise in Hebei Province. Its role as a demonstration leader in technological innovation within the industry has become increasingly prominent.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license